TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06818643: A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 270 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$9,149,910

Rescue Site Savings

+$6,047,580

Unlock Full NCT06818643 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06818643 Rescue Dossier →